Resources from the same session
1687O - PRIMCAT: A novel approach to informing health technology assessment decision making in Australia
Presenter: Fanny Franchini
Session: Proffered paper session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
1688O - Informative censoring of surrogate end-point data in FDA-approved cancer drugs
Presenter: Tomer Meirson
Session: Proffered paper session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
1689O - Comprehensive mapping review of real-world evidence publications focusing on targeted therapies in solid tumors: A collaborative work from ESMO real-world data and Digital Health Working Group
Presenter: Anna Pellat
Session: Proffered paper session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered paper session: Policy and preventive strategies
Resources:
Webcast
1690O - Impact of the SARS-CoV-2 outbreak on the initial clinical presentation of new solid cancer diagnoses: A systematic review and meta-analysis
Presenter: Simon Marty
Session: Proffered paper session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
1691O - Trends in new patient consultations during the COVID-19 pandemic at a comprehensive cancer centre in a public healthcare system
Presenter: Carly Barron
Session: Proffered paper session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
Invited Discussant 1690O and 1691O
Presenter: Luís Castelo-Branco
Session: Proffered paper session: Policy and preventive strategies
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered paper session: Policy and preventive strategies
Resources:
Webcast